ArticleEndocrine connections2026
Thyroid function tests and resting heart rate in Graves' disease: a prospective longitudinal study.
Article in Endocrine connections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Increased resting heart rate (RHR) is a typical sign of thyrotoxicosis. RHR may therefore serve as a monitoring tool, but longitudinal data on continuous measures of RHR and thyroid hormones are sparse. We evaluated the association between continuously monitored RHR and thyroid function tests in Graves' disease (GD). Design: This is a double-center, prospective, longitudinal cohort study in 30 patients with GD on antithyroid drug treatment. Participants were followed up with monthly study visits over six months at two hospitals in Graz, Austria. Methods: Free thyroxine (fT4) and free triiodothyronine (fT3) were measured at each study visit. Participants were encouraged to continuously wear a wristband activity tracker (Fitbit Charge 6) to assess RHR. Associations of RHR (mean value over ten days) with thyroid hormones were determined by generalized estimating equation analyses. Results: From September 2024 to November 2025, we enrolled 30 participants (24 women, mean (SD) age of 40.7 (14.6) years) and performed 176 study visits. Thyrotoxicosis was present in 24 participants (80%) at baseline. One SD increase in RHR of 8.8 beats per minute was associated with fT4 (beta = 0.856, 95% CI: 0.641-1.071, P < 0.001), fT3 (beta = 0.836, 95% CI: 0.620-1.051, P < 0.001), and thyrotoxicosis (odds ratio: 5.134, 95% CI: 2.192-12.025, P < 0.001), respectively. Conclusion: RHR assessed by a wearable device is strongly associated with thyroid hormones in GD. Further trials are required to evaluate whether RHR is useful to guide timing of thyroid function tests during antithyroid drug treatment and for GD diagnostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.